Peptide therapies & emerging science

Investigational biologic therapies

A plain-language look at the newest science aimed at endometriosis — GLP-1 medications, exosomes, and targeted peptides — and how researchers imagine weaving them around excision surgery. This is a map of where the field is heading, not a menu of treatments to ask for.

Abstract white ball-and-stick molecular structures floating on a pale gray field

Modernist watercolour drawing of a seated figure in blush and blue

Please read first

None of the novel therapies described — no GLP-1 medication, exosome therapy, or peptide platform — is FDA-approved to treat endometriosis. Where medications appear, they are approved for other conditions, and any endometriosis use would be off-label and investigational. Decisions about medication or surgery belong to you and your physician.

The landscape at a glance

Modality	Maturity	Evidence base	Nearest clinical horizon
GLP-1 receptor agonists	Emerging clinical	Mechanistic + real-world cohort	Off-label adjunct: now, for select patients
Exosomes / EVs (as disease drivers)	Established preclinical	28+ mechanistic studies (Scheck 2022)	Diagnostic biomarker: 2–5 years
MSC-derived therapeutic EVs	Early preclinical	Animal models only	Clinical trials: 5–10 years
Peptide targeting platforms	Proof-of-concept	Rodent + macaque models	Early-stage studies: 3–7 years
Liposomal / nanocarrier delivery	Preclinical (active)	2023–2025 mouse/macaque models	First human trials possible: ~5 years

01Why endometriosis is hard to treat: four drivers

Inflammation

The fluid around the pelvic organs is rich in inflammatory signals (TNF-α, IL-1β, IL-6). Immune cells that should clear stray endometrial tissue instead get reprogrammed to tolerate it. Notably, GLP-1 — the same hormone the new weight-loss medications mimic — is reduced in the pelvic fluid of people with endometriosis.

Exosomes

Cells release microscopic packages called extracellular vesicles carrying genetic and protein instructions. In endometriosis these messengers help lesions build a blood supply, evade the immune system, and drive scarring — central enough that they're studied both as a target and as a future diagnostic.

Metabolism & insulin resistance

Lesions favor an inefficient, sugar-hungry metabolism, and insulin resistance can raise local estrogen production via aromatase — which feeds lesion growth in an estrogen-dependent disease. This metabolic angle is exactly where GLP-1 medications may fit.

Fibrosis & adhesions

Over time, signals like TGF-β drive scar tissue that binds organs together, distorts anatomy, and amplifies pain. Reducing this fibrosis — ideally with treatments delivered right to the lesion — is an active research direction.

02GLP-1 medications

GLP-1 medications are best known for diabetes and weight loss, but they're also genuinely anti-inflammatory — and that's why endometriosis researchers are interested. The idea is not that these drugs treat endometriosis on their own, but that for someone who already has a reason to take one, the anti-inflammatory and metabolic effects might also help the endometriosis-friendly environment in the body.

Mechanism	What it does	Why it may matter in endo
Calms inflammatory signaling (NF-κB)	Blocks a master switch for inflammation	Lowers TNF-α, IL-6, IL-1β in the pelvic environment
Quiets the inflammasome (NLRP3)	Prevents release of inflammatory messengers	Reduces the inflammatory storm in pelvic fluid
Re-tunes immune cells	Shifts macrophages toward a clean-up phenotype	May restore immune surveillance of stray cells
Improves insulin sensitivity	Lowers insulin resistance	Less aromatase → less local estrogen → less lesion fuel
Anti-fibrotic signal	Dials down TGF-β and scar-forming cells	May slow fibrosis and adhesion formation
Metabolic reprogramming	Disrupts the lesion's preferred fuel use	Creates an environment less friendly to lesions

What the evidence shows so far

Krasnyi et al. (2022): GLP-1 is significantly lower in the pelvic fluid of endometriosis patients, and lower GLP-1 tracked with weaker immune clean-up cells.
Hsieh et al. (2025): a real-world cohort comparing GLP-1 medications vs. metformin in endometriosis patients — the first population-level look at outcomes.
Hagemann et al. (2025): in the lab, semaglutide plus a progestin reduced endometrial cell growth more than either alone.
Sola-Leyva et al. (2025): a review of how GLP-1 medications may affect the uterine lining, and a call for prospective studies.

Important safety points

Not safe in pregnancy — must be stopped at least two months before trying to conceive.
A boxed warning exists for thyroid C-cell tumors seen in rodents; avoided with a personal or family history of medullary thyroid cancer or MEN2.
Common nausea and GI effects can overlap with — and worsen — bowel-related endometriosis symptoms.
Altered digestion can affect absorption of the pill; timing with oral contraceptives matters.
Never a stand-alone endometriosis treatment — only ever alongside established hormonal or surgical care.

03Exosomes & extracellular vesicles

Exosomes are tiny bubbles cells use to send messages to each other. In endometriosis they carry "keep growing" instructions between cells. Scientists are chasing two opportunities: reading these messengers in a blood or fluid sample to diagnose endometriosis without surgery — potentially cutting the notorious 7–10 year diagnostic delay — and one day engineering healthy versions to treat it.

Exosome source	Key cargo	Target cell	Effect
Endometriotic stromal cells	miR-200b, miR-141	Peritoneal lining cells	Helps lesions attach and spread
Endometriotic epithelial cells	VEGF, angiogenic miRNAs	Blood-vessel cells	Builds new vessels that feed lesions
Lesion-derived EVs	lncRNA HOXA11-AS	Immune macrophages	Makes the immune system tolerate lesions
Pelvic fluid EVs	TGF-β1, fibronectin	Fibroblasts	Drives scarring and adhesions
Menstrual fluid EVs	Multiple miRNAs	NK cells	Weakens immune surveillance

04Targeted peptide therapies

Peptides are small protein fragments used here as address labels: attach a peptide that recognizes endometriosis lesions to a drug or particle, so treatment concentrates at the lesion and spares the rest of the body. All of this is at the laboratory and animal stage.

Peptide platform	What it targets	Carrier	Stage
TNYL peptide	EphB4 receptor (lesion blood vessels)	Polymer nanoparticles	Preclinical — macaque
HA-conjugated peptides	CD44 receptor (lesion stromal cells)	Liposomes	Preclinical — mouse
Neutrophil-targeting peptides	Immune-cell surface (hitchhiking)	ROS-responsive liposomes	Preclinical — mouse
Cell-penetrating peptides (CPPs)	Entry into lesion cells	siRNA / miRNA carriers	Early proof-of-concept

05The peptide library — an honest read on each one

These are the peptides people ask about most. For each one: what it's explored for, how it's thought to work, and where the evidence actually sits. Most of them are far less proven than the marketing suggests — that's the point of listing them here.

Reading the structures

Every peptide below is drawn as its own amino-acid chain — each labeled bead is a residue in its real sequence, read left to right, and the links between them are peptide bonds. The color is not decoration: choose what it encodes — the strength of the human evidence, or what the peptide is reached for.

Olive structures. There is real human data — usually for a topical or non-injected route, or an approval outside the US. The strongest tier on this page, and still far from a proven systemic therapy.

1 peptide here

Amber structures. A handful of small human studies, case series, or off-label clinical use — enough to be interesting, not enough to predict safety or benefit for you specifically.

2 peptides here

Clay structures. Cells and animals only. The mechanism may be elegant, but nothing here has been shown to work in a human body at a known dose.

8 peptides here

What this means for the future

Color is a snapshot, not a verdict. A clay structure isn't a dead end — it's a molecule that hasn't been asked the human question yet. What moves a peptide from clay to amber to olive is boring, expensive work: dose-finding, pharmacokinetics, placebo-controlled trials, and long-term safety follow-up. Very few peptides ever make that walk; the ones that do usually arrive looking different from the version sold today.

Near term (1–3 yrs)
Better-run human trials for the handful with plausible mechanisms, plus regulatory tightening on compounded versions. Expect some current favorites to fail outright.
Middle (3–7 yrs)
The real momentum is in targeted delivery — peptides used as address labels on drugs and nanoparticles, so treatment concentrates at a lesion instead of the whole body.
Long (7+ yrs)
If any of this reaches clinic for cluster conditions, it will most likely be as a precise add-on around established care, not as a replacement for surgery, hormonal management or pacing.

Filter by strength of data

Filter by use case

Sort

Showing 11 of 11 peptides. Even the strongest tier here is weak by drug-approval standards.

GHK-Cu

Skin · Collagen

Gly-His-Lys + Cu²⁺

Explored for: A copper-binding tripeptide famous in skincare for collagen support, wound healing, reduced wrinkles/pigmentation, and hair-follicle support.
How it's thought to work: Stimulates collagen, elastin and glycosaminoglycan synthesis, drives skin remodeling and angiogenesis, and has antioxidant/anti-inflammatory activity. Lab studies show collagen production rising substantially.
The evidence: Skin and wound-healing effects are reasonably supported by lab and topical research. The systemic/injected form rests on a much thinner human evidence base.

BPC-157

Healing · Gut

GEPPPGKPADDAGLV (15 aa)

Explored for: A synthetic 15-amino-acid fragment derived from a protein in gastric juice. Most explored — mainly in animals — for healing tendons, ligaments, muscle, and the gut lining, and for calming inflammation.
How it's thought to work: Thought to act like a 'traffic director' at injury sites: modulating growth factors, promoting new blood-vessel formation (angiogenesis), and helping cells migrate into damaged tissue.
The evidence: A July 2025 systematic review screened 544 papers and included 36 studies — only one in humans. There's little reliable human data on safety or effectiveness. The FDA classifies compounded BPC-157 as an unapproved drug and has flagged possible immune reactions.

TB-500

Recovery

Thymosin β4 fragment (43 aa)

Explored for: A lab-made fragment of Thymosin Beta-4, promoted for tissue repair, flexibility, and recovery from muscle/tendon injury.
How it's thought to work: Regulates actin (a cell-structure protein) to help cells migrate to injuries, promotes new blood vessels, mobilizes stem cells, and lowers inflammatory mediators (IL-1, TNF-α).
The evidence: Not FDA-approved, banned by WADA, and sold through the unregulated research market. Human evidence is minimal; enthusiasm outpaces the data.

CJC-1295

Growth · Recovery

Modified GHRH analog (~30 aa)

Explored for: A long-acting version of GHRH (growth-hormone-releasing hormone), used to raise the body's own growth hormone and IGF-1 — promoted for lean mass, fat loss, recovery, and deeper sleep. Often paired with Ipamorelin.
How it's thought to work: Stimulates the pituitary to release growth hormone in a sustained way; the modification extends its half-life so a small weekly dose keeps GH/IGF-1 elevated.
The evidence: Two small human trials (2006, 2013) showed dose-dependent rises in GH and IGF-1. Still not FDA-approved; the FDA specifically warns CJC-1295 carries immunogenicity risk (potentially including anaphylaxis).

Epitalon

Longevity

Ala-Glu-Asp-Gly (4 aa)

Explored for: A four-amino-acid peptide promoted for longevity, telomere support, and better sleep.
How it's thought to work: Can activate telomerase (the enzyme that maintains chromosome-protecting telomere caps); in cell cultures it lengthened telomeres and let cells divide past their usual limit.
The evidence: Evidence is predominantly cell-culture and animal work, plus older Russian clinical observations. Claims of proven human lifespan extension go well beyond the data — no Western randomized trials.

Ipamorelin

Growth · Sleep

Aib-His-D-Trp-D-Phe-Lys (5 aa)

Explored for: A selective growth-hormone secretagogue — the common partner to CJC-1295. Valued for a cleaner GH pulse without much effect on cortisol or appetite; explored for recovery, body composition, and sleep.
How it's thought to work: Acts directly on the pituitary's ghrelin receptor to trigger an immediate pulse of growth hormone — pairing its 'intensity' with CJC-1295's 'sustained availability.'
The evidence: A 1999 human trial showed ipamorelin induces biologically meaningful GH release. Not FDA-approved; the FDA has flagged the same immunogenicity concerns as CJC-1295.

KPV

Anti-inflammatory

Lys-Pro-Val (3 aa)

Explored for: A tiny tripeptide clipped from the tail of alpha-MSH, your body's own anti-inflammatory hormone. Studied for gut inflammation (colitis/IBD) and skin calming — potentially relevant to gut-barrier and MCAS-type pictures.
How it's thought to work: Taken up directly by gut cells via the PepT1 transporter, where it dampens the NF-κB inflammatory pathway and lowers pro-inflammatory cytokines like TNF-α and IL-1β.
The evidence: The strongest single dataset is a 2008 Gastroenterology paper showing oral KPV cut inflammation in two mouse colitis models. Human clinical evidence is still limited; it's being reintroduced to some compounding pharmacies.

MOTS-c

Metabolic

Mitochondrial-derived peptide (16 aa)

Explored for: A peptide your own mitochondria make, studied for insulin sensitivity, metabolic health, muscle function, and healthy aging — nicknamed an 'exercise-mimetic.'
How it's thought to work: Activates the AMPK energy-sensing pathway (by disrupting the folate–methionine cycle), improving how muscle handles glucose and encouraging fat 'browning' and mitochondrial efficiency.
The evidence: Compelling animal and cell data for reversing insulin resistance and diet-induced obesity; human therapeutic use is still investigational. Not FDA-approved.

Selank

Calm · Anxiety

Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 aa)

Explored for: A peptide derived from the immune peptide tuftsin, explored for anxiety, stress resilience, and mild cognitive/mood support without sedation.
How it's thought to work: Thought to modulate GABA and monoamine systems and influence BDNF and enkephalin activity, nudging the stress response toward calm.
The evidence: Mostly Russian preclinical and small human studies. Not FDA-approved; broader, high-quality human trials are lacking.

Semax

Focus · Neuro

Met-Glu-His-Phe-Pro-Gly-Pro (7 aa)

Explored for: An ACTH-fragment peptide used (in Russia) for focus, cognition, and neuroprotection after stroke — popular as a nootropic.
How it's thought to work: Raises BDNF and NGF (nerve growth factors), supports dopamine/serotonin signaling, and appears neuroprotective in models.
The evidence: Approved in Russia for some neurological uses; Western evidence is limited and mostly preclinical. Not FDA-approved.

Thymosin α1

Immune

Thymosin alpha-1 (28 aa)

Explored for: A synthetic copy of a natural thymus peptide that tunes immune function — studied for viral infections, immune deficiency, and as a cancer adjunct.
How it's thought to work: Enhances T-cell function and helps regulate (not suppress) immune responses, with some anti-inflammatory effect.
The evidence: Has the most real-world use of this group — approved in several countries (as Zadaxin) for certain infections. Still not FDA-approved in the U.S. for general wellness use.

If you're going to do this anyway

What to look for in good, clean peptide care

Plenty of people will try peptides regardless of how thin the evidence is. If that's you, the question stops being whether the science is settled and becomes whether the care around it is clean. Here's the standard worth holding out for — and the signs you're being sold to rather than treated.

Real physician oversight

A licensed clinician who takes a full history, examines you, and puts the peptide in the context of your other conditions and medications — not a questionnaire, a sales call, or a coach with a supplier. They should be willing to say no, and to document what they prescribed and why.

Baseline labs and a monitoring plan

Bloods before you start and at sensible intervals after — glucose/HbA1c, metabolic panel, and IGF-1 for anything touching growth hormone. If nobody suggests measuring anything, nobody can tell whether it's working or harming you.

A licensed compounding pharmacy

Dispensing should come from a state-licensed (ideally 503A/503B) pharmacy against a real prescription in your name. Vials that arrive from a website labeled 'research use only, not for human consumption' were never made to be put in a body.

Clean formulation, and proof of it

Ask for a batch-specific third-party certificate of analysis: identity, purity (typically >98%), and testing for endotoxin, heavy metals and residual solvents. Ask what's in it besides the peptide — preservatives, diluents and excipients matter enormously if you have MCAS.

Written dosing, storage and sterile technique

Exact dose in micrograms, reconstitution instructions, refrigeration and shelf life after mixing, and single-use sterile supplies. Sloppy handling is a more likely source of harm than the molecule itself.

A defined trial with an end date

Good care sets out what you're measuring, how long the trial runs, and what result means stop. A clear taper or exit plan should exist before the first injection — open-ended prescriptions are a business model, not a treatment.

Honest framing of the evidence

A trustworthy prescriber will tell you unprompted that most of this is off-label, unapproved, and largely animal-derived, and will name the specific human studies they're relying on. Certainty is the warning sign; nuance is the credential.

Somewhere for it to go wrong

A named person to contact for side effects, a documented reporting route, and notes shared with your regular doctors. Care that leaves no trace in your medical record leaves you alone with the consequences.

Red flags — walk away

No prescription, no exam, no medical history taken.
Vials sold as 'research chemicals', or bought through social media, a gym, or a group chat.
No certificate of analysis available, or one that isn't tied to your batch number.
Bundles, subscriptions, stacks, or pressure to buy several peptides at once.
Cure language — for endometriosis, hEDS, long COVID, autoimmunity or 'inflammation' in general.
The person recommending it also profits from selling it.

Green flags — good signs

One peptide at a time, so you can actually attribute any change.
The clinician raises risks before you do, and knows your cancer and endo history.
Lowest effective dose, short defined course, planned reassessment.
Everything documented and shared with your GP or specialist.
Willingness to tell you that boring things — sleep, pacing, PT, iron, hormones — should come first.

Before anyone injects anything

Peptide safety, plainly

Peptides are marketed as gentle because they're small and 'natural'. Small doesn't mean safe — it means under-studied. Most of what's sold in this space sits outside the system that normally catches harm.

Most of these are not approved drugs

In the US, many research peptides are unapproved for any use, and the FDA has moved several — including BPC-157 — into a category that bars compounding pharmacies from making them. 'Research use only' on a label means it was never assessed for human safety.

Purity and dose are the real risk

Gray-market vials are frequently mislabeled, under- or over-dosed, or contaminated with endotoxin and residual solvents. Independent testing repeatedly finds contents that don't match the label. There is no batch accountability when something goes wrong.

Growth signalling deserves caution

Anything that promotes new blood vessels, cell migration or growth-hormone release is, by definition, also promoting growth in tissue you don't want to grow. That matters with endometriosis, adenomyosis, a personal or family cancer history, or an undiagnosed lump.

Immune and mast-cell reactivity

Injected peptides can provoke immune responses and injection-site reactions. If you have MCAS or a history of reacting to excipients, preservatives and diluents are as relevant as the peptide itself.

Interactions and masking

Peptides can shift glucose, blood pressure, fluid balance, thyroid and IGF-1 — which can interfere with existing medication and, worse, blur symptoms you were tracking to get a diagnosis. Several are also banned in tested sport.

Pregnancy, fertility and the unknown

There is essentially no safety data in pregnancy, breastfeeding, or on long-term fertility for the peptides on this page. Absence of reported harm is not evidence of safety when nobody has looked.

Questions worth asking a prescriber

What human evidence exists for this peptide, for my condition — not for a related one?
Where is it sourced, and can I see a third-party certificate of analysis for this batch?
What are we measuring to decide it's working, and by when do we stop if it isn't?
What does it do to my other conditions, medications, and any tissue I don't want stimulated?
What's the exit plan — how do I come off it, and what happens if I do?

Stop and get seen if

Any new lump, unusual bleeding, or rapidly changing pain.
Signs of an allergic or systemic reaction — spreading rash, swelling, wheeze, faintness.
Injection-site heat, spreading redness, or fever, which can mean infection.
Sudden changes in vision, severe headache, chest pain, or new numbness.
Blood sugar, blood pressure, or heart-rate swings outside your usual pattern.

Educational only, and not medical advice or an endorsement of any peptide. Nothing on this page is a recommendation to start, source, or self-administer a compound. Decisions belong to you and a clinician who knows your full history.

Layered onto expert care

Weaving it together around surgery

For most people, expert excision surgery plus hormonal management remains the foundation of care. The therapies above are imagined as add-ons layered around that foundation — never a replacement.

Foundation
Today's standard of care
Excision, hormones, pain care
Everything else layers onto — never replaces — this: expert excision surgery as the gold standard for diagnosis and treatment; hormonal suppression afterward (continuous pill, progestin IUD, or GnRH agents); pain management (NSAIDs, neuropathic agents, pelvic PT); and structured symptom tracking at baseline, 3, 6, and 12 months.
Phase 1
0–3 months before surgery
Calm the ground first
Goal: reduce inflammation, optimize the metabolic environment, and potentially simplify lesions before excision. For eligible patients, this is where a GLP-1 medication or dietary and metabolic optimization might be started, with baseline symptom and metabolic measures recorded.
Phase 2
Surgery day to 8 weeks
Protect and prevent scarring
Standard adhesion barriers (Seprafilm / Interceed) are used today. A GLP-1 medication started before surgery may be continued to blunt inflammation. Investigational-only ideas — targeted liposomal delivery, EV-modified peritoneal lavage — are not yet in practice. If pregnancy or IVF is planned, GLP-1 medication is stopped well in advance.
Phase 3
3–12+ months after surgery
Maintain and prevent recurrence
Goal: prevent recurrence, address lingering inflammation, maintain symptom control, and preserve fertility. Hormonal suppression at 3–6 months, quality-of-life tracking at 3, 6 and 12 months, metabolic monitoring at 6 months, and — one day — EV recurrence surveillance.

The 5–10+ year horizon

Technology	The promise	The key barrier
MSC-exosome therapy	Disease-modifying, non-hormonal, fertility-preserving	Manufacturing, standardization, first-in-human safety
Peptide-guided exosome delivery	Precision delivery to lesions only	Hitting the target in varied lesion types
Exosome liquid-biopsy diagnosis	Ends the 7–10 year diagnostic delay	Validation in large, diverse populations
Dual GLP-1 + hormonal therapy	Better recurrence prevention than either alone	Needs full trials and a regulatory pathway
Gene therapy via nanoparticles	Durable lesion suppression without systemic hormones	Control and safety of gene delivery

How progress gets measured

Timepoint	Questionnaires	Research biomarkers
Baseline (pre-op)	EHP-30, pain scores, ENDOPAIN-4D	HbA1c, fasting insulin, HOMA-IR; serum exosome panel
3 months post-op	EHP-30 + pain scores	Metabolic panel if on GLP-1
6 months post-op	EHP-30 + pain scores + ENDOPAIN-4D	Repeat metabolic panel; GLP-1 dose review
12 months post-op	EHP-30 + pain scores	Recurrence check (ultrasound ± MRI); exosome panel
Ongoing (every 6 months)	EHP-5 (short form)	BMI, metabolic markers, reproductive tracking